id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2528-0007,FDA,FDA-2016-E-2528,"Determination of Regulatory Review Period for Purposes of Patent
Extension; BRIVIACT ORAL TABLETS, New Drug Application 205836",Notice,Determinations,2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,2020-02-11T04:59:59Z,2019-12-12T14:29:37Z,2019-26813,0,0,0900006484206ad6
FDA-2016-E-2528-0006,FDA,FDA-2016-E-2528,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T17:19:37Z,,0,0,0900006484115ddd
FDA-2016-E-2528-0005,FDA,FDA-2016-E-2528,Letter from U.S. Patent and Trademark Office to  FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T16:38:16Z,,0,0,090000648378ce56
FDA-2016-E-2528-0004,FDA,FDA-2016-E-2528,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-01-19T05:00:00Z,2017,1,2017-01-19T05:00:00Z,,2017-01-19T12:40:58Z,,0,0,0900006482484220
FDA-2016-E-2528-0003,FDA,FDA-2016-E-2528,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-09-26T04:00:00Z,2016,9,2016-09-26T04:00:00Z,,2016-09-26T16:15:46Z,,0,0,0900006482267dd3
FDA-2016-E-2528-0002,FDA,FDA-2016-E-2528,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T18:56:40Z,,0,0,0900006482198ba6
FDA-2016-E-2528-0001,FDA,FDA-2016-E-2528,"Patent Extension Application from Harness, Dickey & Pierce P.L.C. (on behalf of UCB Biopharma SPRL)",Other,Application,2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T18:50:04Z,,0,0,0900006482198ba2